| 2024-09-13 | -0.42 % |
|
| 2024-09-12 | +2.74 % |
|
| 2024-09-10 | +2.87 % |
|
| 2024-09-06 | -0.06 % |
|
| 2024-09-05 | -0.45 % |
|
| 2024-08-15 | +0.27 % |
|
| 2024-08-14 | +0.22 % |
|
| 2024-08-09 | -2.55 % |
|
| 2024-08-08 | +2.15 % |
|
| 2024-08-07 | -0.26 % |
|
| 2024-08-06 | -0.86 % |
|
| 2024-08-05 | -2.53 % |
|
| 2024-07-31 | -2.55 % |
|
| 2024-07-25 | +4.1 % |
|
| 2024-07-23 | -1.71 % |
|
| 2024-07-22 | -0.21 % |
|
| 2024-07-18 | +0.29 % |
|
| 2024-07-17 | +2.32 % |
- Summary: Gilead Sciences' stock (GILD) increased by 2.32%, with recent developments including the departure announcement of its Chief Medical Officer, Dr. Merdad Parsey, alongside positive ratings from various financial firms based on promising data from clinical studies and drug pipeline advancements.
Reason for Stock Increase: The stock of Gilead Sciences (GILD) went up due to positive developments such as upgrades by financial firms based on promising data from clinical studies, drug pipeline advancements, and the company's strong outlook in the biopharmaceutical sector.
- The article discusses a comparison between Galapagos (NASDAQ: GLPG) and Acerus Pharmaceuticals (OTCMKTS: ASPCF) as small-cap medical companies, with Galapagos being favored due to a higher consensus target price indicating a potential upside of 30.83%, stronger institutional ownership, and better financial performance metrics compared to Acerus Pharmaceuticals. The increase in Gilead Sciences (GILD) stock by 2.32% is likely due to positive news, market sentiment, or general market conditions.
|
| 2024-07-11 | +1.77 % |
|
| 2024-07-08 | +1.29 % |
|
| 2024-07-02 | -0.35 % |
- Gilead Sciences (GILD) stock was -0.35% down last night, as Chief Medical Officer Merdad Parsey sold 2,000 shares at $68.63 per share, totaling over $137,260, through a pre-arranged trading plan, but it was seen as a routine financial move, not a lack of confidence in the company's future prospects, with recent positive developments in the medical field and Gilead's strong market position highlighted, reflecting its continued attractiveness to investors despite challenges in the oncology sector.
- The article discusses a recent insider sale of Gilead Sciences Inc (GILD) stock by their Chief Medical Officer Merdad Parsey, leading to a decrease in the stock price, which is attributed to a broader trend of insider selling within the company, with eight insider sells and no insider buys over the past year, and the stock being currently assessed as Fairly Valued according to GF Value estimate, hence potentially affecting investor confidence in the company's future prospects.
|
| 2024-07-01 | +0.04 % |
|
| 2024-06-27 | -0.69 % |
|
| 2024-06-26 | -0.43 % |
|
| 2024-06-21 | +3.18 % |
|
| 2024-06-20 | +8.46 % |
|
| 2024-06-18 | -1.74 % |
|
| 2024-06-14 | +2.36 % |
- The article is about Gilead Sciences (GILD) stock, which increased by 2.36% last night; the stock likely went up due to positive news, such as strong financial performance, new product developments, or favorable market conditions.
- The article highlights various U.S. stock movements, with Gilead Sciences (GILD) stock rising 2.8% due to rumors surrounding its secretive obesity drug program.
- The article discusses insider transactions at Arcellx, Inc., with Chief Medical Officer Christopher Heery selling shares, acquiring shares through option exercises, and the potential impact on the company's valuation. Gilead Sciences (GILD) stock potentially saw an increase due to Arcellx's strategic partnership with GILD, upcoming trial data, and positive analyst sentiments.
- The article discusses that Gilead Sciences (GILD) stock rose by 2.36%, attributing this increase to the positive results and data presented at the 2024 European Hematology Association Annual Congress, highlighting the successful manufacturing and product characteristics of Yescarta in second-line treatment of relapsed/refractory large B-cell lymphoma, as well as supporting the safety and feasibility of outpatient administration of both Yescarta and Tecartus.
|
| 2024-06-10 | +0.85 % |
|
| 2024-06-06 | -0.05 % |
|
| 2024-06-05 | -0.44 % |
|
| 2024-06-04 | +1.15 % |
|
| 2024-06-03 | -1.31 % |
- The article discusses updated four-year overall survival data from the pivotal ZUMA-3 study evaluating the CAR T-cell therapy Tecartus in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia, showing a median overall survival of 25.6 months and a four-year overall survival rate of 40%. Gilead Sciences stock (GILD) may have gone down due to other factors affecting the overall market sentiment or investor perception, rather than this specific news about the positive outcomes of the CAR T-cell therapy study.
- The article discusses a new Chinese patent for RedHill Biopharma's opaganib in combination with immune checkpoint inhibitors (ICIs) to induce an anti-cancer immune response, resulting in a market decline for Gilead Sciences (GILD) stock due to the potential competition in the cancer treatment market from this development.
- The article discusses various stock options for investors focusing on potential dividend gains, with Gilead Sciences (GILD) being one of the highlighted companies, but the stock declined for numerous reasons including concerns about patent expirations, possible U.S. government-imposed price restrictions, the expectation of higher interest rates, and reduced future earnings value in valuation models.
- The article provides information on a pilot study by Kite, a Gilead Company, which demonstrated the well-tolerated and potentially effective use of Yescarta in patients with central nervous system lymphoma. However, Gilead Sciences (GILD) stock went down last night due to various factors impacting the overall market sentiment and not directly related to the study results.
|
| 2024-05-31 | +0.3 % |
- The article discusses Gilead Sciences' (GILD) announcement of detailed results from the Phase 3 EVOKE-01 study, which showed positive outcomes for their drug Trodelvy in treating metastatic non-small cell lung cancer (NSCLC), leading to a 0.3% increase in GILD stock last night; the stock went up due to the encouraging results from the study, which demonstrated a reduction in the risk of death and an improved overall survival rate in patients with NSCLC who had progressed on previous treatments, hinting at a potential new treatment option for a patient population with significant unmet medical needs.
- The article discusses that Gilead Sciences' stock (GILD) was 0.3% up last night despite Trodelvy, their drug, failing to improve survival for patients with advanced bladder cancer and showing only modest benefits in late-stage lung cancer, which raised concerns about the drug's growth prospects. The stock may have gone up due to positive results in other trials and potential future combinations with drugs like Keytruda for lung cancer treatment.
- The article discusses that Gilead Sciences Inc's stock, GILD, was up by 0.3% with the announcement of positive topline results from the Phase 3 TROPiCS-04 study on Trodelvy in treating locally advanced or metastatic urothelial cancer, leading to the stock increase.
|
| 2024-05-30 | +0.91 % |
- The article reports that Gilead Sciences' stock (GILD) was up by 0.91% last night, and the increase in the stock price could be attributed to positive developments or news outside the information provided in the article.
- The article discusses Gilead Sciences' stock, which was up 0.91% last night, and attributes this increase to the announcement of topline results from a Phase 3 study evaluating Trodelvy in patients with urothelial cancer. The study did not meet its primary endpoint of overall survival, but showed numerical improvements favoring Trodelvy in specific subgroups and secondary endpoints, despite a higher number of deaths due to adverse events with Trodelvy compared to standard chemotherapy. Gilead Sciences will further investigate the data and discuss next steps with the FDA for this potential treatment option for metastatic urothelial cancer that has accelerated approval based on tumor response rate.
- The article discusses key hires at Energy Recovery, Inc., with Ricardo Freitas and Matt Hostetler joining in leadership roles, aiming to support the company's growth strategy. The stock of Gilead Sciences (GILD) went up by 0.91% last night, but this increase is not directly related to the content of the article on Energy Recovery, Inc., so the reason for the rise in Gilead Sciences stock would need to be looked into separately.
|
| 2024-05-29 | -0.69 % |
|
| 2024-05-24 | -0.74 % |
|
| 2024-05-23 | -2.4 % |
|
| 2024-05-22 | +0.76 % |
|
| 2024-05-21 | -0.9 % |
|
| 2024-05-14 | +0.16 % |
- The article discusses how Gilead Sciences' stock (GILD) increased by 0.16% after Zacks Research lowered its Q3 2024 earnings estimates for the biopharmaceutical company, with Gilead Sciences' previously reported earnings beating analysts' expectations and various research analysts adjusting their ratings and price targets for the company; the stock went up due to positive earnings results and analyst outlook adjustments.
- Gilead Sciences stock was up 0.16% last night, despite underperforming the broader market year-to-date, as Wall Street analysts maintain cautious optimism about its future potential.
- Summary: International Assets Investment Management LLC recently purchased a new stake in the biopharmaceutical company Gilead Sciences, Inc. (NASDAQ:GILD), contributing to the 0.16% increase in the stock. Other institutional investors and hedge funds have also adjusted their holdings, potentially influencing the stock's rise.
Reason for Stock Increase: The increase in Gilead Sciences (GILD) stock can be attributed to the recent purchase of shares by International Assets Investment Management LLC and other institutional investors, showing confidence in the company's future performance.
- The article discusses Gilead Sciences' (GILD) stock increase of 0.16% and attributes this rise to the positive news surrounding the company's advancements in Chimeric Antigen Receptor (CAR) T-cell therapy with their drug Yescarta. This includes presentations at the upcoming European Hematology Association Annual Congress, showcasing real-world experiences and improved outcomes for patients with complex and hard-to-treat blood cancers, highlighting their progress in the field.
- The article discusses Xilio Therapeutics' pipeline progress and business updates, particularly focusing on their tumor-activated immuno-oncology therapies. Gilead Sciences' stock went up, likely due to their exclusive license agreement with Xilio for the tumor-activated IL-12 program and positive pipeline advancements, such as the Phase 2 trial initiation for XTX101 and XTX301, scheduled to report clinical data later this year.
|
| 2024-05-10 | +2.14 % |
|
| 2024-05-09 | -0.52 % |
- Summary: Gilead Sciences (GILD) stock was down by 0.52%, trading at $65 per share, due to falling sales of its Covid-19 treatment Veklury and recent underperformance compared to the S&P 500 index, with potential gains expected in the future as market sentiments improve and the company's cash position remains stable.
Reason for Gilead Sciences (GILD) stock decline: The stock has been weighed down by falling sales of its Covid-19 treatment Veklury, recent underperformance compared to the S&P 500 index, and uncertainties in the macroeconomic environment with high oil prices and elevated interest rates.
- The article discusses Royalty Pharma's strong financial performance, strategic acquisitions, commitment to dividend growth, and potential for sustained growth in the pharmaceutical royalty space, highlighted by a 14% growth in Royalty Receipts and the acquisition of royalties on Sanofi's frexalimab. The decline in Gilead Sciences (GILD) stock may be due to investors shifting focus towards Royalty Pharma's positive developments and growth prospects.
- The article discusses Gilead Sciences (GILD) and its collaborator, Arcellx, providing updates on their anito-cel multiple myeloma program, with a focus on the iMMagine-3 trial. The GILD stock went down -0.52% likely due to broader market conditions, investor sentiment, or specific industry news affecting biopharmaceutical stocks.
- The article provides an update on Gilead Sciences' partnership with Arcellx for their anitocabtagene autoleucel program, including the launch of a Phase 3 trial named iMMagine-3, aiming to evaluate the efficacy of anito-cel in patients with multiple myeloma. The stock of Gilead Sciences (GILD) went down by -0.52% possibly due to various factors influencing the stock market, such as market conditions, investor sentiment, or company-specific news.
|
| 2024-05-07 | -0.12 % |
|
| 2024-05-06 | +1.17 % |
- Summary: Gilead Sciences (GILD) stock went up because the company's drug opaganib received a new Chinese patent for inhibiting single-stranded RNA virus replication, notably Ebola, through 2035, showcasing promising results in treating Ebola virus disease and demonstrating potential benefits for various indications, including COVID-19 and acute respiratory distress syndrome.
Reason for Stock Increase: The increase in Gilead Sciences (GILD) stock is attributed to the positive news regarding opaganib receiving a new Chinese patent, which enhances its global intellectual property portfolio, demonstrates efficacy against Ebola virus disease, shows synergistic effects with other treatments like remdesivir, and highlights its potential in addressing multiple indications, such as COVID-19 and acute respiratory distress syndrome, leading to investor optimism in the company's future prospects.
|
| 2024-05-03 | -0.84 % |
|
| 2024-04-30 | -1.12 % |
|
| 2024-04-29 | +0.79 % |
- The article discusses Gilead Sciences (GILD) stock, which was up by 0.79% the previous night, and provides details on analyst ratings and target price changes for the company. The stock went up likely due to positive earnings results released on April 25th, where the company reported earnings per share that beat estimates and an increase in revenue compared to the same quarter the previous year.
- The article discusses an expanded research agreement between Atossa Therapeutics and Weill Cornell Medicine to explore the potential synergy between antibody drug conjugates (ADCs) and (Z)-endoxifen in treating breast cancer, leading to a 0.79% increase in Gilead Sciences (GILD) stock due to the potential advancements in oncology research.
- The article discusses Valmark Advisers Inc. decreasing its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 14.6%, along with other hedge funds buying and selling shares of the company, various research firms' ratings on GILD stock, quarterly earnings data released by Gilead Sciences, Inc., announcement of a quarterly dividend, and recent insider stock sale by Merdad Parsey. Gilead Sciences' stock went up possibly due to the overall positive quarterly earnings data surpassing analysts' estimates.
- The article discusses how Gilead Sciences (GILD) stock went up by 0.79%, with Truist Financial Corp reducing its position in GILD by 13.9% in the 4th quarter, while several other hedge funds and institutional investors made changes to their positions in the stock, and insider Merdad Parsey sold 2,000 shares. The stock went up likely due to positive earnings results, including beating analysts' estimates and an increase in quarterly revenue.
- The article discusses Gilead Sciences (GILD) stock, which went up by 0.79%, with various analysts providing ratings, price targets, and updates on the company's performance. The stock price experienced this increase after the company reported better-than-expected earnings results, beating analysts' estimates and showing revenue growth.
|
| 2024-04-26 | +0.23 % |
|
| 2024-04-25 | -2.7 % |
- The article discusses Gilead Sciences (GILD) stock, which experienced a -2.7% decrease last night, and provides a detailed financial summary of the company's performance, including an increase in total worldwide sales, growth in oncology and vaccines, and regulatory and clinical progress. The stock could have gone down due to a variety of reasons, such as market conditions, investor sentiment, or company-specific factors that may have impacted investor confidence in Gilead Sciences.
- Gilead Sciences (GILD) stock was down by 2.7% last night; the market experienced a mixed day with positive domestic equities and a weakening rupee against the dollar, but Gilead Sciences stock specifically may have gone down due to factors such as company-specific news, broader market trends, or investor sentiment.
- Summary: Gilead Sciences (GILD) stock dropped by 2.7% following its first-quarter earnings report, where it beat sales forecasts primarily due to its Covid treatment, Veklury, but saw lower-than-expected sales for two of its cancer drugs.
Reason for stock drop: Gilead Sciences' stock went down due to its cancer drugs Tecartus and Trodelvy not meeting sales expectations, even though its Covid treatment Veklury surpassed projections.
- Gilead Sciences (GILD) stock was down by -2.7% last night, and the overall market saw various movements with gains and losses in different sectors and stocks, including notable performances like Inox Wind announcing bonus shares, Sensex rallying nearly 500 points, and Kirloskar Pneumatic Company Ltd's stock surging after announcing financial results; GILD stock declined due to various factors, such as market sentiment, economic indicators, foreign capital outflows, and company-specific news impacting investor confidence.
|
| 2024-04-24 | +0.07 % |
- The article discusses Gilead Sciences, Inc. (NASDAQ: GILD) stock being slightly up, with analysts lowering their FY2024 EPS estimates for Gilead Sciences due to the company's expected earnings per share decrease; the stock may have gone up due to potential future performance, a current market trend, or investor sentiment.
- The article discusses how Gilead Sciences' (GILD) stock was up by 0.07% and provides insights into analysts' revised earning estimates for the company, with a decrease in EPS forecast for Q2 2024. The stock may have increased due to investor sentiment, potential market factors, or other positive news impacting the company.
- Gilead Sciences (GILD) stock went up by 0.07% last night as the company is engaged in a digital transformation journey, including a migration to SAP S/4HANA and collaboration with SAP on innovative solutions like SAP Batch Release Hub for Life Sciences, aimed at ensuring compliance with regulatory standards and maintaining quality and safety standards for its products, ultimately safeguarding patient wellbeing globally.
|
| 2024-04-23 | +0.12 % |
- Summary: Lindbrook Capital LLC increased its stake in Gilead Sciences, Inc. (NASDAQ:GILD), leading to a slight uptick of 0.12% in the company's stock, with other institutional investors also adding to their positions in the biopharmaceutical firm.
Reason for Gilead Sciences (GILD) stock increase: The increase in stake by Lindbrook Capital LLC and other institutional investors such as Morgan Stanley, Northern Trust Corp, Pacer Advisors Inc., AQR Capital Management LLC, and Clearbridge Investments LLC contributed to the rise in Gilead Sciences' stock as they showed confidence in the company's growth potential.
- The article discusses how Gilead Sciences' stock increased by 0.12%, with reasons possibly including institutional investments and hedge fund activity, as well as positive earnings results despite missing estimates. Several hedge funds have recently bought shares of Gilead Sciences, while research analysts have given the company varying ratings from sell to buy, with an average hold rating. Syndicates have also decreased their target prices for the stock, with recent insider selling mentioned. Gilead Sciences is a biopharmaceutical company that develops and commercializes medicines for various medical needs.
- The article discusses Ligand Pharmaceuticals' financial results announcement and business model, emphasizing partnerships with leading pharmaceutical companies including Gilead Sciences. Gilead Sciences' stock went up by 0.12% likely due to positive developments related to their partnership with Ligand Pharmaceuticals.
|
| 2024-04-22 | +0.28 % |
- The article discusses how Gilead Sciences' (GILD) stock was up 0.28% last night, with Verdence Capital Advisors LLC reducing its holdings in the company, and other hedge funds changing their positions; the stock went up due to the positive changes in holdings by institutional investors and the company announcing a boost in its quarterly dividend.
- The article compares Vivesto (OTCMKTS: OASMY) and Galapagos (NASDAQ: GLPG) based on institutional ownership, valuation, earnings, profitability, and analyst recommendations, concluding that Galapagos has higher revenue, earnings, net margins, return on equity, and return on assets compared to Vivesto. Gilead Sciences (GILD) stock went up due to positive market sentiment and strong performance indicators of other medical companies like Galapagos.
- The article compares Gilead Sciences (GILD) and Mesoblast (MESO) as potential investment options in the medical industry, indicating that Gilead Sciences stock went up last night by 0.28%, possibly due to factors such as higher revenue and earnings compared to Mesoblast, lower volatility, stronger institutional ownership, and analyst price targets suggesting some upside potential.
- The article discusses Gilead Sciences' stock being up by 0.28% and how StockNews.com lowered their rating on the stock from strong-buy to buy, despite several other analysts dropping their price targets and ratings on Gilead Sciences. The stock saw an increase likely due to positive reactions from some analysts who maintained a buy or outperform rating, which helped boost investor confidence in the company's potential.
- The article discusses Oppenheimer reaffirming their outperform rating on Gilead Sciences (GILD) stock with a $105.00 price objective, and mentions other research firms' ratings; Gilead Sciences stock went up by 0.28% likely due to positive ratings from analysts and the company's recent dividend increase along with revenue consistency.
|
| 2024-04-19 | +0.91 % |
|
| 2024-04-18 | -1.15 % |
- The U.S. Food and Drug Administration announced that cancer therapies using CAR-T technology, including Gilead Sciences' products like Tecartus and Yescarta, will require changes to their warning labels due to the serious risk of T-cell blood cancer, leading to Gilead Sciences (GILD) stock going down by -1.15% last night.
- The article discusses the nomination of Norbert Bischofberger, Ph.D. and Ramy Farid, Ph.D. to the Board of Directors of Vir Biotechnology, Inc., which caused Gilead Sciences' stock to go down as Dr. Bischofberger, a former Executive Vice President at Gilead Sciences, may be leaving Vir's Board to join Kronos Bio, Inc. This change in leadership and potential impact on Vir's direction likely contributed to the decline in Gilead Sciences' stock price.
|
| 2024-04-17 | -0.56 % |
|
| 2024-04-16 | -0.65 % |
|
| 2024-04-11 | +0.78 % |
|
| 2024-04-10 | -2.6 % |
- The article discusses the 12 best depressed stocks to buy in 2024, mentioning various companies like Gilead Sciences, Inc. (GILD) among others, with GILD stock down by -2.6% the previous night. The stock market experienced a decline as JPMorgan Chief Jamie Dimon warned about high stock valuations, geopolitical tensions, and potential rise in interest rates to as much as 8%. The concerns over valuations have led to a selloff, but long-term investors view this as a buying opportunity amidst the ongoing bullish market sentiments. The reason for the decline in Gilead Sciences' stock could be attributed to the broader market trends and concerns highlighted by Dimon regarding the current economic environment and potential future scenarios.
- The article discusses Compugen Ltd.'s cancer immunotherapy candidate COM503 targeting the IL-18 pathway and its collaboration with Gilead Sciences (GILD). Gilead Sciences (GILD) stock went down by -2.6% due to factors such as uncertainties related to clinical trials, market conditions, and the unproven nature of Compugen's computational drug discovery approach.
- Summary: Nurix Therapeutics, Inc. announced the extension of their strategic collaboration with Gilead Sciences, presented new case studies, and shared financial results for the first quarter which led to a -2.6% decrease in Gilead Sciences (GILD) stock.
Reason for Gilead Sciences (GILD) stock drop: The decrease in Gilead Sciences (GILD) stock may be attributed to various factors such as financial results of Nurix Therapeutics, Inc., potential uncertainties related to the collaboration with Nurix, and overall market conditions.
|
| 2024-04-09 | +0.75 % |
|
| 2024-04-08 | -0.23 % |
- Summary: Ligand Pharmaceuticals Incorporated presented new data on Captisol-enabled™ Topiramate Injection as a potential replacement therapy for certain neurological conditions during the 9th London-Innsbruck Colloquium. Gilead Sciences (GILD) stock went down by -0.23% last night.
Answer: Gilead Sciences (GILD) stock may have decreased due to various reasons, including market conditions, investor sentiment, industry news, or company-specific developments, and not necessarily related to the content of the article about Ligand Pharmaceuticals and Captisol-enabled™ Topiramate Injection.
- The article discusses RedHill Biopharma's corporate transformation towards U.S. government-funded pipeline development, highlighting advanced clinical development programs for drugs like opaganib and RHB-107 focused on nuclear/chemical exposure and viral pandemic scenarios, leading to Gilead Sciences (GILD) stock closing -0.23% down last night. The stock possibly went down due to new developments and focus in the biopharma industry that may have impacted investor sentiment towards Gilead Sciences.
- The article discusses a study on mRNA-4157 (V940) individualized neoantigen therapy combined with pembrolizumab in patients with HPV-negative head and neck squamous cell carcinoma, showing preliminary positive clinical responses and disease control, with indications of immune response activation, suggesting that the gilead sciences(GILD) stock might have gone down due to the release of this study results impacting investor sentiment.
- The article announces that Gilead Sciences, Inc. (Nasdaq: GILD) will release its first quarter 2024 financial results and guidance on April 25, 2024, but the stock went down by 0.23% last night; the stock might have declined due to various factors such as market conditions, investor sentiment, or company performance expectations.
|
| 2024-04-05 | +0.04 % |
- Summary: Gilead Sciences (GILD) stock was up 0.04% last night, while Arcus Biosciences, Inc. (NYSE: RCUS) experienced a drop in shares by 2.8%. The increase in Gilead Sciences stock can be attributed to major shareholder Gilead Sciences, Inc. purchasing a significant amount of Arcus Biosciences shares, which may have positively impacted investor sentiment.
Reason for Gilead Sciences (GILD) stock increase: Major shareholder Gilead Sciences, Inc. purchased a large number of Arcus Biosciences shares, indicating confidence in the company's future prospects and potentially contributing to the positive performance of Gilead Sciences stock.
- The article discusses how MacroGenics has achieved progress with its drug vobra duo in treating metastatic castration-resistant prostate cancer, leading to a reduced rate of patient discontinuations in the ongoing phase 2 TAMARACK study, resulting in Gilead Sciences (GILD) stock going up, following the announcement of the positive safety data.
- The article reports that Ballentine Partners LLC increased their stake in Gilead Sciences by 60.4% in the fourth quarter, which contributed to Gilead Sciences' stock going up by 0.04%; the stock also saw increases in holdings from other large investors, analysts upgrading rating, and a stakeholder selling company shares. Gilead Sciences' stock may have gone up due to increased confidence from these actions of large investors and analysts upgrading the stock to a "strong-buy" rating.
- The article discusses Deutsche Bank's cautious stance on Bristol-Myers Squibb (NYSE:BMY) stock following the FDA approval of Abecma for the KarMMA-3 trial, citing concerns about its adoption in earlier treatment lines and lack of overall survival benefit compared to standard of care. The rise in Gilead Sciences (NASDAQ:GILD) stock can be attributed to its recent partnership with Tennessee Oncology, which was highlighted as a unique arrangement not typically seen in community practice groups, showcasing potential growth opportunities for investors seeking value.
|
| 2024-04-03 | -1.66 % |
|
| 2024-04-02 | -1.08 % |
- The article discusses the recent insider selling activity of Gilead Sciences, where the Chief Medical Officer sold 2,000 shares, leading to a 1.08% decrease in the stock price. The sale was part of a pre-arranged trading plan and does not necessarily indicate lack of confidence in the company, as insiders may sell for personal financial management reasons.
- The article announces the appointment of Mehul Joshi as the Chief Financial Officer of Pulmonx Corporation and highlights his extensive experience in finance, including previous roles at companies like Gilead Sciences. Gilead Sciences (GILD) stock went down by 1.08% possibly due to factors unrelated to this specific announcement, such as market conditions, industry news, or company performance.
- The article discusses Gilead Sciences (GILD) extending its research collaboration with Nurix Therapeutics, potentially leading to significant future milestones and royalty payments, but the stock went down by -1.08% last night for various market-related reasons.
|
| 2024-04-01 | -0.51 % |
|
| 2024-03-28 | +0.33 % |
- The article discusses Xilio Therapeutics raising $11.3 million in private-placement financing, and the positive impact on the stock of Gilead Sciences (GILD) by investing $13.5 million in Xilio as part of a licensing agreement, leading to GILD's stock rising by 0.33% due to this investment.
- The article discusses Xilio Therapeutics' strategic portfolio reprioritization and a private placement agreement with investors, including Gilead Sciences, Inc., contributing to GILD stock's 0.33% increase due to enabling clinical development of promising cancer therapies.
- The article discusses that Xilio Therapeutics (XLO) stock surged after signing an exclusive license agreement with Gilead Sciences (GILD), causing Gilead stock to increase by 0.33%.
- Gilead Sciences (GILD) stock went up by 0.33% following an exclusive license agreement with Xilio Therapeutics Inc (XLO) to develop and commercialize Xilio's Phase 1 tumor-activated IL-12 program, XTX301, which helped boost investor confidence and drive the stock price higher.
- Summary: Gilead Sciences (GILD) stock was up by 0.33% last night due to positive financial results and recent highlights reported by Assembly Biosciences, Inc., including progress on their antiviral pipeline and partnerships.
Reason for Gilead Sciences (GILD) stock increase: The positive financial results and recent developments reported by Assembly Biosciences, highlighting progress in their antiviral pipeline and partnership with Gilead, likely contributed to the uptick in Gilead Sciences (GILD) stock.
|
| 2024-03-27 | +0.83 % |
|
| 2024-03-26 | -0.23 % |
- The article discusses the recent decrease of 0.23% in Gilead Sciences, Inc. (GILD) stock, citing potential reasons such as varying hedge funds' holdings, mixed ratings from brokerages, recent insider transactions of share selling, and the company's financial performance, including a recent dividend increase and higher payout ratio in the quarter.
- The article discusses research notes on Arcus Biosciences stock (NYSE:RCUS) by various analysts and the recent activity in its shares, which opened at $16.49 on Monday. The drop in Gilead Sciences (GILD) stock may be due to major shareholder Gilead Sciences, Inc. buying a significant number of shares of Arcus Biosciences' stock, leading to a potential shift in investment focus.
- The article discusses institutional investments in Gilead Sciences (GILD) stock, with CVA Family Office LLC acquiring shares during the fourth quarter alongside other institutional investors making changes to their positions, while various equities research analysts have downgraded or maintained ratings on the stock; the recent quarterly earnings report of Gilead Sciences showed a decrease in revenue compared to the previous year, leading to a decrease in stock value, and insiders selling company shares may have also impacted the stock's performance.
|
| 2024-03-25 | -0.04 % |
|
| 2024-03-22 | -0.66 % |
- The article discusses Nkarta (NKTX) stock plummeting after the biotech company shifted focus from a cancer drug to an experimental lupus treatment, causing a 31.3% drop in stock price; this news might have impacted Gilead Sciences (GILD) stock negatively, as the company's Kite division is also involved in testing drugs with similar natural killer cells technology used by Nkarta, potentially leading to investor concerns about competition and market demand for similar treatments.
- Summary: Gilead Sciences (GILD) completed the acquisition of CymaBay Therapeutics, resulting in a decrease in both GAAP and non-GAAP earnings per share (EPS) for 2024 by approximately $3.35 to $3.45, which contributed to the decline in Gilead Sciences stock by -0.66%.
Reason for Gilead Sciences (GILD) stock decline: The acquisition of CymaBay Therapeutics and associated costs are expected to result in a decrease in Gilead's earnings per share (EPS) for 2024, leading to the stock decline.
- The article announces Gilead Sciences' completion of the acquisition of CymaBay Therapeutics, Inc., which is expected to enhance Gilead's liver disease treatment portfolio, but the stock of Gilead Sciences(GILD) experienced a -0.66% decrease likely due to the acquisition costs, associated operating expenses, and lower interest income related to the transaction.
|
| 2024-03-21 | -1.2 % |
|
| 2024-03-19 | +0.2 % |
|
| 2024-03-18 | -0.58 % |
|
